Farringdon Capital, Ltd. Charles River Laboratories International, Inc. Transaction History
Farringdon Capital, Ltd.
- $198 Billion
- Q1 2025
A detailed history of Farringdon Capital, Ltd. transactions in Charles River Laboratories International, Inc. stock. As of the latest transaction made, Farringdon Capital, Ltd. holds 2,471 shares of CRL stock, worth $348,336. This represents 0.19% of its overall portfolio holdings.
Number of Shares
2,471Holding current value
$348,336% of portfolio
0.19%Shares
1 transactions
Others Institutions Holding CRL
# of Institutions
651Shares Held
55.1MCall Options Held
695KPut Options Held
809K-
Vanguard Group Inc Valley Forge, PA6.11MShares$861 Million0.02% of portfolio
-
Black Rock Inc. New York, NY5.09MShares$717 Million0.02% of portfolio
-
Wellington Management Group LLP Boston, MA4.29MShares$604 Million0.13% of portfolio
-
Ubs Group Ag2.39MShares$337 Million0.07% of portfolio
-
Kayne Anderson Rudnick Investment Management LLC Los Angeles, CA1.95MShares$275 Million0.75% of portfolio
About CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- Ticker CRL
- Exchange NYSE
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 50,863,300
- Market Cap $7.17B
- Description
- Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Ass...